^
    Back
    Association details:
    Biomarker:MYD88 mutation
    Cancer:Waldenstrom Macroglobulinemia
    Drug:Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Dasatinib In Waldenström Macroglobulinemia

    Excerpt:
    ...- Known tumor expression of mutated MYD88 performed by a CLIA certified laboratory....
    Trial ID:
    NCT04115059
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2018
    Title:

    IBRUTINIB SHOWS PROLONGED PROGRESSION-FREE SURVIVAL IN SYMPTOMATIC, PREVIOUSLY TREATED PATIENTS WITH MYD88 MUTATED WALDENSTROM'S MACROGLOBULINEMIA: LONG-TERM FOLLOW-UP OF PIVOTAL TRIAL (NCT01614821).

    Published date:
    05/17/2018
    Excerpt:
    The 5-year overall survival for all patients was 87%, and 93% and 80% for MYD88MutCXCR4WT and MYD88MutCXCR4Mut patients, respectively (Log-rank p=0.41)...ibrutinib is highly active and produces long-term responses in symptomatic patients with relapsed and refractory WM
    Trial ID:
    NCT01614821
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    Ibrutinib Dose Reduction Does Not Affect Progression-Free Survival in Patients with Waldenstrom Macroglobulinemia

    Excerpt:
    We evaluated 217 consecutive patients with the clinicopathological diagnosis of WM who were symptomatic and received treatment with ibrutinib....Factors associated with a worse PFS were...CXCR4 mutations (HR 3.0, 95% CI 1.5-6.0; p=0.001). Expression of mutated MYD88 (HR 0.01, 95% CI 0.00-0.09; p<0.001)...were associated with a better PFS.
    DOI:
    10.1182/blood-2018-99-111626